148 related articles for article (PubMed ID: 21861933)
1. Intracellular trafficking as a determinant of AS-DACA cytotoxicity in rhabdomyosarcoma cells.
Wolf SJ; Huynh T; Bryce NS; Hambley TW; Wakelin LP; Stewart BW; Catchpoole DR
BMC Cell Biol; 2011 Aug; 12():36. PubMed ID: 21861933
[TBL] [Abstract][Full Text] [Related]
2. Sequestration of AS-DACA into acidic compartments of the membrane trafficking system as a mechanism of drug resistance in rhabdomyosarcoma.
Williams M; Catchpoole D
Int J Mol Sci; 2013 Jun; 14(7):13042-62. PubMed ID: 23799359
[TBL] [Abstract][Full Text] [Related]
3. In vitro assessment of novel transcription inhibitors and topoisomerase poisons in rhabdomyosarcoma cell lines.
Wolf SJ; Wakelin LP; He Z; Stewart BW; Catchpoole DR
Cancer Chemother Pharmacol; 2009 Nov; 64(6):1059-69. PubMed ID: 19277661
[TBL] [Abstract][Full Text] [Related]
4. Up-regulation of GLI1 in vincristine-resistant rhabdomyosarcoma and Ewing sarcoma.
Yoon JW; Lamm M; Chandler C; Iannaccone P; Walterhouse D
BMC Cancer; 2020 Jun; 20(1):511. PubMed ID: 32493277
[TBL] [Abstract][Full Text] [Related]
5. CD133 marks a myogenically primitive subpopulation in rhabdomyosarcoma cell lines that are relatively chemoresistant but sensitive to mutant HSV.
Pressey JG; Haas MC; Pressey CS; Kelly VM; Parker JN; Gillespie GY; Friedman GK
Pediatr Blood Cancer; 2013 Jan; 60(1):45-52. PubMed ID: 22408058
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxic drugs in combination with the CXCR4 antagonist AMD3100 as a potential treatment option for pediatric rhabdomyosarcoma.
Regenbogen S; Stagno MJ; Schleicher S; Schilbach K; Bösmüller H; Fuchs J; Schmid E; Seitz G
Int J Oncol; 2020 Jul; 57(1):289-300. PubMed ID: 32377699
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of cytotoxicity of N-[2-(dimethylamino)ethyl] acridine-4-carboxamide and of its 7-chloro derivative: the roles of topoisomerases I and II.
Bridewell DJ; Finlay GJ; Baguley BC
Cancer Chemother Pharmacol; 1999; 43(4):302-8. PubMed ID: 10071981
[TBL] [Abstract][Full Text] [Related]
8. Selective cellular uptake and retention of SN 28049, a new DNA-binding topoisomerase II-directed antitumor agent.
Chen YY; Lukka PB; Joseph WR; Finlay GJ; Paxton JW; McKeage MJ; Baguley BC
Cancer Chemother Pharmacol; 2014 Jul; 74(1):25-35. PubMed ID: 24801172
[TBL] [Abstract][Full Text] [Related]
9. From amsacrine to DACA (N-[2-(dimethylamino)ethyl]acridine-4-carboxamide): selectivity for topoisomerases I and II among acridine derivatives.
Finlay GJ; Riou JF; Baguley BC
Eur J Cancer; 1996 Apr; 32A(4):708-14. PubMed ID: 8695277
[TBL] [Abstract][Full Text] [Related]
10. Are myogenin and myoD1 expression specific for rhabdomyosarcoma? A study of 150 cases, with emphasis on spindle cell mimics.
Cessna MH; Zhou H; Perkins SL; Tripp SR; Layfield L; Daines C; Coffin CM
Am J Surg Pathol; 2001 Sep; 25(9):1150-7. PubMed ID: 11688574
[TBL] [Abstract][Full Text] [Related]
11. Topoisomerase I/II selectivity among derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA).
Bridewell DJ; Finlay GJ; Baguley BC
Anticancer Drug Des; 2001 Dec; 16(6):317-24. PubMed ID: 12375884
[TBL] [Abstract][Full Text] [Related]
12. Differentiation of rhabdomyosarcoma cell lines using retinoic acid.
Barlow JW; Wiley JC; Mous M; Narendran A; Gee MF; Goldberg M; Sexsmith E; Malkin D
Pediatr Blood Cancer; 2006 Nov; 47(6):773-84. PubMed ID: 16283617
[TBL] [Abstract][Full Text] [Related]
13. [Analysis of vesicle subpopulations carrying early endosomal autoantigen EEA1].
Zlobina MV; Kamentseva RS; Kornilova ES; Kharchenko MV
Tsitologiia; 2014; 56(10):741-8. PubMed ID: 25711083
[TBL] [Abstract][Full Text] [Related]
14. Cetuximab promotes immunotoxicity against rhabdomyosarcoma in vitro.
Herrmann D; Seitz G; Warmann SW; Bonin M; Fuchs J; Armeanu-Ebinger S
J Immunother; 2010 Apr; 33(3):279-86. PubMed ID: 20445348
[TBL] [Abstract][Full Text] [Related]
15. The modulation of iron metabolism affects the Rhabdomyosarcoma tumor growth in vitro and in vivo.
Asperti M; Cantamessa L; Gryzik M; Bugatti M; Codenotti S; Denardo A; Vermi W; Fanzani A; Poli M
Clin Exp Med; 2023 Oct; 23(6):2487-2502. PubMed ID: 36764998
[TBL] [Abstract][Full Text] [Related]
16. PDK-1/AKT pathway as a novel therapeutic target in rhabdomyosarcoma cells using OSU-03012 compound.
Cen L; Hsieh FC; Lin HJ; Chen CS; Qualman SJ; Lin J
Br J Cancer; 2007 Sep; 97(6):785-91. PubMed ID: 17848913
[TBL] [Abstract][Full Text] [Related]
17. Modulation of HLA class I expression in multidrug-resistant human rhabdomyosarcoma cells.
Melguizo C; Prados J; Marchal JA; Vélez C; Carrillo E; Boulaiz H; Sánchez-Montesinos I; Madeddu R; Aránega A
Neoplasma; 2003; 50(2):91-6. PubMed ID: 12740641
[TBL] [Abstract][Full Text] [Related]
18. Cellular uptake of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA).
Haldane A; Finlay GJ; Hay MP; Denny WA; Baguley BC
Anticancer Drug Des; 1999 Jun; 14(3):275-80. PubMed ID: 10500502
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxic and DNA-damaging properties of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) and its analogues.
Pastwa E; Ciesielska E; Piestrzeniewicz MK; Denny WA; Gniazdowski M; Szmigiero L
Biochem Pharmacol; 1998 Aug; 56(3):351-9. PubMed ID: 9744573
[TBL] [Abstract][Full Text] [Related]
20. Potent oncolytic activity of multimutated herpes simplex virus G207 in combination with vincristine against human rhabdomyosarcoma.
Cinatl J; Cinatl J; Michaelis M; Kabickova H; Kotchetkov R; Vogel JU; Doerr HW; Klingebiel T; Driever PH
Cancer Res; 2003 Apr; 63(7):1508-14. PubMed ID: 12670897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]